USFDA booster for Sun Pharma

The stock of Sun Pharma is likely to witness buying interest as the company got permission from the US Federal Drug Administration for its Ultram ER tablets, a pain relieving drug. According to a notice issued to the BSE, the company has said that its subsidiary got an approval from the US authority for its abbreviated new drug application to market a generic version of Ultram ER, Tramadol hydrochloride extended release tablets. According to the company, Tramadol HCL ER tablets have annual sales of nearly $125 million in the US. Shares of Sun Pharma on Friday closed at Rs 512.40 on the BSE, down 1.19 per cent from its previous day close.